Slows down cognitive decline by 27% after 18 months and 21.3% of those who received the drug experienced brain swelling or brain bleeding, while only 9.3% of those on a placebo had those problems.
Should be interesting to see how much Biogen, Eisai and BioArctic stock will have increased by close.